PROJECTS
95+ GMP, biomanufacturing, cleanroom, and R&D facility builds — by region, status, and developer. We track every project here; and specialize in helping owners and construction management teams recruit the PMs, CQV, and process crews who deliver them.
Use the navigation below to jump directly to the regional section you want. Each section is organized by status and project type.
Five projects whose scale, scope, or strategic positioning mark them as defining builds for the 2025–2030 life sciences construction cycle.
Eli Lilly’s largest single capital investment in company history and the anchor of a $50B+ U.S. expansion program. The LEAP Innovation Park is a multi-building biomanufacturing campus designed for next-generation small molecule API production and biologics capacity, supporting Lilly’s GLP-1, oncology, and immunology pipelines.
The largest pharmaceutical manufacturing expansion in Europe. Novo’s Kalundborg campus is the global anchor for semaglutide (Ozempic / Wegovy) production, with multiple new manufacturing buildings supporting active pharmaceutical ingredient (API) and fill-finish capacity for the GLP-1 portfolio.
Eli Lilly’s North Carolina manufacturing campus expanding biologics drug substance capacity. Part of the company’s broader $50B+ U.S. capital program supporting GLP-1 and biologics demand.
Major expansion of Novo Nordisk’s U.S. fill-finish operations supporting semaglutide and other GLP-1 product capacity. Adds significant API, formulation, and packaging capacity to the existing site.
One of the largest CDMO (contract development and manufacturing organization) biologics facilities under construction globally. Multiple cGMP biomanufacturing buildings supporting end-to-end drug substance and drug product production for partner pharma clients.
Organized by region. We track every project below; on select builds we’re actively recruiting senior PM, superintendent, MEP, commissioning, validation (CQV), GMP-experienced cleanroom, and process-engineering roles.
Major expansion of Vertex’s Seaport headquarters anchoring the company’s gene-editing and cystic fibrosis pipeline R&D.
Expansion of Moderna’s flagship mRNA manufacturing campus supporting respiratory, oncology, and rare-disease vaccine portfolios.
New Moderna biomanufacturing site expanding clinical and commercial mRNA production capacity in the I-495 belt.
CDMO biomanufacturing site supporting cell therapy, viral vector, and biologics drug substance capacity.
Expansion of Sanofi’s Cambridge research footprint anchoring U.S. R&D operations.
BMS’s expanded cell therapy manufacturing site supporting CAR-T pipeline production capacity.
Continued expansion of BMS’s Devens biologics manufacturing site supporting drug substance and drug product capacity.
Expansion of Takeda’s Cambridge research and discovery footprint.
AstraZeneca’s expanded Waltham R&D presence supporting U.S. oncology and rare disease research.
Pfizer’s consolidated Cambridge R&D footprint supporting U.S. discovery and translational research.
CDMO biomanufacturing site supporting cell and gene therapy clinical trial supply for partner pharma clients.
BioNTech’s U.S. research hub anchoring oncology and immunology pipeline development.
Continued expansion of Novartis’s flagship U.S. R&D campus in Kendall Square.
Moderna’s announced New Hampshire biomanufacturing expansion supporting mRNA portfolio capacity.
Major Regeneron expansion at the Tarrytown campus supporting U.S. discovery and biologics manufacturing.
Merck’s major Linden biomanufacturing expansion supporting oncology and vaccine drug substance capacity.
Pfizer’s Andover biomanufacturing expansion supporting biologics drug substance capacity.
Sanofi Pasteur’s flagship U.S. vaccine plant expansion supporting respiratory and pediatric vaccine production.
J&J Janssen’s flagship U.S. HQ campus with continued expansion across R&D and biomanufacturing buildings.
BMS’s New Brunswick biomanufacturing campus expansion supporting drug substance and drug product capacity.
Bayer’s U.S. research center expansion supporting pharmaceutical discovery operations.
WuXi STA’s U.S. API manufacturing campus supporting CDMO production for partner pharma clients.
GSK’s U.S. R&D headquarters expansion supporting discovery and translational research.
J&J’s Spring House R&D campus expansion supporting consumer health and pharma discovery.
Major expansion of Merck’s Elkton VA vaccine plant supporting pediatric and HPV vaccine production.
Roche Diagnostics campus expansion supporting U.S. diagnostics and molecular research operations.
Vaccine fill-finish capacity expansion in the U.S. supporting Bavarian Nordic’s mpox, smallpox, and travel vaccine portfolio.
Lonza’s Northeast U.S. CDMO expansion supporting biologics drug substance capacity for partner pharma clients.
Amgen’s Holly Springs drug product manufacturing facility expanding biologics fill-finish capacity in the U.S.
Eli Lilly’s RTP biomanufacturing expansion supporting biologics drug substance capacity, part of the broader $50B+ U.S. program.
Resilience’s RTP CDMO site supporting cell therapy, viral vector, and biologics drug substance capacity.
Genentech’s North Carolina biomanufacturing expansion supporting U.S. drug substance capacity.
Pfizer’s Sanford manufacturing expansion supporting biologics and vaccine drug substance capacity.
Merck’s Wilson NC sterile manufacturing expansion supporting biologics drug product capacity.
Merck’s Durham vaccine manufacturing facility with continued capacity additions for pediatric and HPV vaccine production.
Continued expansion of Novo Nordisk’s Clayton fill-finish operations supporting GLP-1 product capacity.
Novartis’s RTP discovery and translational research site expansion supporting U.S. pipeline development.
WuXi Biologics U.S. expansion supporting CDMO drug substance capacity (multi-site).
New translational research building expanding Duke’s academic medical R&D and biotechnology footprint.
Catalent’s Greenville sterile fill-finish expansion now operating under Novo Nordisk ownership.
UNC Chapel Hill’s translational medicine and biomedical research expansion.
Major Eli Lilly Research Laboratories expansion at the Indianapolis flagship campus supporting biologics and small molecule R&D.
Eli Lilly’s Pleasant Prairie biomanufacturing site supporting biologics and GLP-1 production capacity.
Novo Nordisk’s Bloomington fill-finish facility (acquired Catalent operations) supporting GLP-1 portfolio capacity.
Pfizer’s Kalamazoo sterile manufacturing site expansion supporting U.S. drug substance and drug product capacity.
AbbVie’s North Chicago campus expansion supporting biologics and small molecule production capacity.
Catalent’s Madison biologics CDMO facility now operating under Novo Nordisk ownership.
Boehringer Ingelheim’s St. Joseph animal health manufacturing expansion.
AstraZeneca’s Mt. Vernon vaccine manufacturing site expansion supporting U.S. respiratory vaccine production.
Eli Lilly’s announced Limerick PA expansion supporting U.S. manufacturing capacity (note: distinct from Limerick Ireland).
New biological sciences research building expanding academic medical R&D footprint.
Resilience’s Chicago CDMO site supporting biologics drug substance and drug product capacity for partner clients.
Bayer’s St. Louis campus expansion supporting U.S. research and adjacent biotech operations.
Lonza’s Houston biomanufacturing site (acquired Genentech facility) supporting CDMO drug substance capacity.
TMC Helix Park life sciences campus development supporting academic research, biotech tenants, and translational medicine.
Resilience’s Texas CDMO biomanufacturing site supporting drug substance and drug product capacity.
UT Austin’s expanded life sciences research building supporting biotech and biomedical engineering academic programs.
Continued buildout of Lilly’s Concord NC biomanufacturing campus following the initial $4.4B Phase 1 announcement.
Pfizer’s Rocky Mount sterile manufacturing site rebuild and expansion following 2023 tornado damage.
Continued expansion of Genentech’s flagship campus anchoring U.S. discovery research and biologics manufacturing.
Genentech’s Oceanside biologics manufacturing expansion supporting U.S. drug substance capacity.
Amgen’s flagship campus expansion supporting biologics R&D and manufacturing capacity.
Gilead’s Foster City headquarters and R&D expansion supporting U.S. discovery research.
Illumina’s genomics platform expansion across California sites supporting sequencing R&D and instrumentation.
Lilly’s San Diego research campus supporting West Coast discovery and translational research.
BMS’s San Diego research site supporting U.S. discovery and translational research for the oncology pipeline.
Vertex’s San Diego research site supporting West Coast discovery and gene editing pipeline.
Genentech’s Oregon biomanufacturing capacity addition supporting U.S. drug substance production.
BI’s Fremont biologics manufacturing expansion supporting U.S. CDMO operations.
Cytiva’s Logan UT bioprocessing consumables expansion supporting global biomanufacturing supply chain.
Bayer’s Berkeley campus expansion supporting U.S. biologics research and manufacturing.
UCSF’s Mission Bay research building expansion supporting biotech and biomedical research adjacencies.
Stanford’s expanded biomedical research pavilion supporting translational and discovery science.
Moderna’s Canadian mRNA vaccine manufacturing site supporting domestic and global supply.
Sanofi’s Toronto vaccine plant expansion supporting flu and respiratory vaccine production.
AstraZeneca’s Mississauga site supporting biologics drug substance production for Canada and global supply.
Major science and engineering research building expanding U of T’s biotechnology and life sciences research capacity.
Eli Lilly’s Ireland biomanufacturing site supporting biologics drug substance capacity for the European market.
Catalent (now Novo Nordisk) Ireland fill-finish expansion supporting European supply chain.
AbbVie’s Ireland manufacturing expansion supporting biologics and small molecule production.
Pfizer’s Grange Castle expansion supporting biologics drug substance and drug product capacity.
BioNTech’s Marburg mRNA vaccine manufacturing expansion supporting oncology and infectious disease portfolios.
BioNTech’s flagship Mainz HQ expansion supporting discovery and translational research.
Roche’s flagship Basel campus expansion supporting global R&D and headquarters operations.
Roche’s Penzberg biomanufacturing expansion supporting global biologics drug substance capacity.
Lonza’s flagship Visp site expansion supporting biologics and mammalian cell culture capacity.
Lonza’s UK biomanufacturing site supporting CDMO drug substance and drug product capacity.
Novartis’s Basel headquarters and manufacturing expansion supporting biologics and small molecule production.
AstraZeneca’s flagship Cambridge UK Discovery Centre supporting global R&D operations.
GSK’s Stevenage UK R&D campus expansion supporting global discovery and translational research.
Sanofi’s Frankfurt industrial park expansion supporting insulin and biologics drug substance capacity.
Sanofi Pasteur’s flagship French vaccine plant expansion supporting global vaccine supply.
J&J Janssen’s Beerse Belgian R&D campus expansion supporting global discovery operations.
BI’s flagship Vienna biopharmaceuticals plant expansion supporting global drug substance capacity.
World’s largest single-site biomanufacturing facility on completion. Samsung Biologics Plant 5 adds 180,000L of mammalian cell culture capacity to the company’s Songdo bio-complex.
WuXi Biologics’s anchor China site expansion supporting CDMO drug substance capacity.
Amgen’s Singapore biomanufacturing expansion supporting Asia-Pacific drug substance capacity.
Sanofi’s Singapore vaccine manufacturing site supporting Asia-Pacific supply.
Takeda’s Japanese biomanufacturing expansion supporting domestic and global biologics supply.
CSL Behring’s Australia plasma-derived therapy manufacturing expansion supporting global supply.
Every project shown is compiled from public filings, company announcements, regulatory disclosures, and our own placement work. We surface projects with confirmed sponsor at announcement, permitting, construction, or operational stages.
To appear in the tracker, a project must meet at least three of the following criteria:
We refresh continuously as projects are announced, status changes occur, or capacity figures are updated. The tracker is maintained by iRecruit.co’s research team in coordination with our placement work. Verify all data before referencing in formal documents. Some project specifics ($ figures, GC assignments, timelines) may have evolved since compilation.
If you’re researching biomanufacturing or pharma R&D projects, you’re likely also evaluating the workforce, GMP credentials, ISPE CPIP, and process-engineering realities that shape execution on builds like these.
iRecruit.co’s specialty recruiting practice for senior life sciences construction roles — cGMP-experienced PMs, commissioning agents, CQV, process engineers.
See our recruiting practice →The state of life sciences construction: cGMP cleanroom infrastructure, GLP-1 capacity, gene therapy, fill-finish, and the workforce needed to deliver them.
Read the guide →BCxP, CxA, CQV and the L1–L5 commissioning sequence — what each signals on life sciences cGMP builds.
Read the guide →iRecruit.co recruits the project managers, superintendents, MEP coordinators, CQV / commissioning agents, and cGMP cleanroom specialists who deliver builds like these. 30-minute scoping call gets you a concrete proposal within 48 hours.
